How Highmark Is Achieving the Triple Aim for ESKD Patients

THE GOAL

Achieve the Triple Aim
The shift toward value-based healthcare is providing a substantial opportunity to improve patient care experiences and clinical outcomes while reducing costs. While many providers and health plans are deploying chronic care management programs for the general patient population, few are pulling ahead of the curve to launch comprehensive models of care that address the unique needs of the highest-risk, most medically complex outlier groups, such as patients with end stage kidney disease (ESKD).

Patients with ESKD
- Demonstrate needs that are often unmet by the traditional fragmented fee-for-service health care system
- Comprise 0.2% of the entire patient population
- Comprise 1% of the Medicare population but 7% of overall costs
- Are hospitalized nearly 2 times per year
- Have a 35% readmission rate

Clinical Needs and Utilization
- Comprise 0.2% of the entire patient population
- Comprise 1% of the Medicare population but 7% of overall costs
- Are hospitalized nearly 2 times per year
- Have a 35% readmission rate

Quality and Patient Experience
- Take more than 19 pills a day
- Dialyze 12–15 hours a week, if receiving in-center hemodialysis
- Have a 78% diabetes comorbidity rate
- Have a 98% hypertension comorbidity rate
- Spend approximately 11 days per year in the hospital

THE CHALLENGE

Managing Medically Complex ESKD Patients
Highmark recognized that its Medicare Advantage and commercially insured ESKD patients would benefit from an enhanced level of complex care management. In 2013, the population had more than $13 million in addressable costs, with an average of two hospitalizations and 13 hospital days per patient per year.

Highmark members benefited from an aligned health system and a physician network that enhanced care coordination for approximately 30 percent of its ESKD population. However, capability gaps and lack of care team alignment remained challenges.

How would Highmark implement a comprehensive care management program for ESKD patients that would improve the quality of care delivery and patient quality of life, while simultaneously reducing costs?
THE SOLUTION
An Innovative ESKD Model of Care
Highmark wanted to partner with an industry leader that could provide advanced care management capabilities and deploy a collaborative model to align incentives. Highmark developed a partnership with DaVita Integrated Kidney Care (IKC) to implement an ESKD model of care that encompassed kidney care management and dialysis coordination.

ESKD Model of Care

Kidney-Focused Care Management Capabilities:
Capabilities included risk stratification, predictive modeling, ESKD care pathways and comorbidity management.

Multidisciplinary Care Team:
Kidney nurses worked with nephrologists, dialysis clinics and hospitals to coordinate care plans and coach patients.

Clinical Data Sharing:
Nurses tracked fluid alerts, missed treatments, labs and meds, and communicated care plan adjustments.

Renal Pharmacy:
Targeted medication reviews reduced medication-related hospitalizations.

Aligned Incentives:
Highmark, DaVita IKC and nephrologists shared savings based on clinical innovation and efficiencies.

Late Stage CKD Interventions:
Nephrologists focused on home modalities and starting patients with access in place.

THE IMPACT
Improved Outcomes and Reduced Costs
By partnering with DaVita IKC to create a comprehensive, evidence-based program to manage ESKD patients across the care continuum, Highmark advanced the Triple Aim. Year-over-year comparisons that span the duration of the program show continuous reduction in admits, central venous catheters (CVCs) and addressable costs.

Annual Results

<table>
<thead>
<tr>
<th></th>
<th>Year 1</th>
<th>Year 2</th>
<th>Year 3</th>
<th>Year 4</th>
<th>Year 5</th>
<th>Year 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Admit Rate Reduction vs. Baseline</td>
<td>24%</td>
<td>29%</td>
<td>25%</td>
<td>37%</td>
<td>31%</td>
<td>37%</td>
</tr>
<tr>
<td>CVC Rate Reduction vs. Baseline</td>
<td>17%</td>
<td>47%</td>
<td>48%</td>
<td>54%</td>
<td>40%</td>
<td>29%</td>
</tr>
<tr>
<td>Addressable Cost Savings vs. Annualized Targets</td>
<td>10%</td>
<td>26%</td>
<td>22%</td>
<td>24%</td>
<td>17%</td>
<td>22%</td>
</tr>
</tbody>
</table>

As a result, Highmark improved ESKD patient quality of care, enhanced patient quality of life and reduced unnecessary costs by more than $18 million over six years.